Authors: C Fotopoulou, R Bowen, R Manchanda, A Michael, S McCormack, A Ullmann, A Wesselbaum, B Levick, R Miller
Published: Future Oncology, 2025
View publication
Aim
To investigate current management of advanced epithelial ovarian cancer (OC) in the UK.
Materials & methods
A cross-sectional survey with 55 healthcare professionals involved in the care of OC patients was conducted via telephone/videoconference in March/May 2023.
Results
Respondents reported that homologous recombination deficiency (HRD) status and brca mutations were routinely tested before planning maintenance treatment. All respondents agreed that cytoreductive surgery should be considered at first recurrence, and 65% recommended using the Descriptive Evaluation of Preoperative Selection Criteria for Operability in Recurrent Ovarian Cancer (DESKTOP) III criteria to guide secondary cytoreduction. Platinum responders typically receive poly (ADP-ribose) polymerase inhibitor maintenance therapy, regardless of HRD status.
Conclusions
Respondents reinforce that most primary OC patients in the UK have known HRD and BRCA mutation status, and the role of secondary cytoreduction is increasingly recognized.
